Business Context and Reporting Period
This Form 8-K filing by Medtronic Plc (Medtronic) reports on events occurring on March 7, 2019. The primary event is the completion of a significant debt offering by Medtronic Global Holdings S.C.A. ("Medtronic Luxco") to refinance existing obligations and fund tender offers.
Key Financial Metrics and Transaction Details
Debt Issuance: Medtronic Luxco issued approximately €7.0 billion in aggregate principal amount of senior notes across six series:
- €500 million Floating Rate Senior Notes due 2021 (EURIBOR + 0.200%)
- €1.5 billion 0.000% Senior Notes due 2021
- €1.5 billion 0.375% Senior Notes due 2023
- €1.5 billion 1.125% Senior Notes due 2027
- €1.0 billion 1.625% Senior Notes due 2031
- €1.0 billion 2.250% Senior Notes due 2039
Proceeds and Liquidity: Net proceeds from the offering are expected to be approximately €6.9 billion after deducting underwriting discounts and offering expenses.
Use of Proceeds: Funds will be utilized to:
- Fund tender offers for outstanding notes issued by Medtronic, Inc. and Covidien International Finance S.A.
- Pay accrued interest, premiums, fees, and expenses related to the tender offers.
- Repay Medtronic Luxco's €1.0 billion 1.700% senior notes due March 28, 2019.
- Support a redemption of certain outstanding notes at an anticipated aggregate price of approximately $1.0 billion.
- General corporate purposes.
Guarantees: The notes are fully and unconditionally guaranteed by Medtronic Plc and Medtronic, Inc.
Material Changes and Strategic Actions
The filing details a major capital structure optimization. The company is replacing existing debt with new senior notes at varying maturities and interest rates. This transaction facilitates the tender offer for approximately $2.1 billion in aggregate principal amount of notes, with a maximum purchase price of approximately $3.8 billion. The company also plans to redeem certain outstanding notes at an aggregate price of approximately $1.0 billion.
Guidance, Outlook, and Management Commentary
Management stated that the updated financial guidance provided on February 19, 2019, for the full fiscal year 2019 is not expected to be affected by the tender offers, the €7.0 billion note offering, the repayment of the 2019 notes, or the redemption of outstanding notes. Furthermore, the company reiterated that it remains comfortable with the consensus earnings per share estimates for fiscal year 2020 as of the February 19, 2019 earnings call.
Investor Verification Checklist
- Verify the final net proceeds received from the €7.0 billion offering after all fees and expenses.
- Confirm the final acceptance rate and total cost of the tender offers for the outstanding notes.
- Review the specific terms of the redemption of the approximately $1.0 billion in outstanding notes.
- Monitor the impact of the new debt structure on the company's weighted average cost of debt and interest coverage ratios.
- Check subsequent filings for the listing status of the new notes on the New York Stock Exchange.